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The objective of this investigation was to analyze possible 
association between BclI polymorphism of glucocorticoid 
receptor gene and obesity in patients with bronchial asthma 
(BA). The study involved 188 patients with bronchial asth-
ma and 95 apparently healthy adult individuals. Generally 
accepted assessments and examinations for BA diagnosis, 
and anthropometric, molecular-genetic and statistic meth-
ods of investigation were used in the research. It was found 
out that the patients with BA demonstrated higher body 
mass index (BMI) and higher ratio of fat centralization much 
more often, than the control group. Genotypes distribution 
for BclI polymorphism in patients with BA showed a sta-
tistically significant difference between patients with differ-
ent BMI unlike the control group. Comparison of genotype 
frequency for BclI polymorphism in glucocorticoid receptor 
gene in individuals with different ratio of fat centralization in 
the control group and in the patients with BA separately 
showed statistically significant differences in the distribution 
of gene allelic variations only among the patients with BA. It 
was demonstrated that G/G genotype in the patients with 
visceral obesity was associated with BA. 
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Introduction. A plenty of evidence concerning the 
role of obesity in bronchial asthma occurrence (BA) 
[1, 2] and deterioration of BA control [3] has been 
reported in recent years. Thus, more than 40 
crosso-ver studies and case-control investigations 
showing the connection between BA and obesity 
have been carried out since 1990.  
The mechanisms of this association have not 
been studied well yet, but their comprehension in-
cludes the following complex of factors: food with a 
low antioxidant value; low physical activity; gastro-
esophageal reflux disease; mechanical restrictions 
of respiratory movements volume caused by tho-
racicoabdominal fat depot; systemic inflammations 
induced by mediators of adipose tissue; genetic 
fac-tors [1, 4, 5]. 
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Obesity contributes not only to occurrence of BA, 
but also to more severe BA course due to caus-ing a 
certain phenotype of disease and decreasing the 
effectiveness of treatment. Still, the associated 
pathogenic mechanisms in BA and obesity require 
further studies. This problem borders on three di-
rections of scientific research: investigation of the 
metabolic disorders in obesity; further conceptual 
development of BA as a chronical disease, accom-
panied by a persistent inflammation; search for their 
common genetic determinants.  
BA and obesity are multifactorial diseases, 
which are influenced by both genetic factors and 
environmental factors [6]. It is assumed that the 
common genetic factors of these two diseases can 
partly explain the data of epidemiological 
investigations, which confirm a close association 
between BA and obesity. More than 100 genes 
were found associated with BA occurrence and, in 
particular, with allergen-specific IgE production 
(atopy), development of bronchial hyperreactivity, 
synthesis of mediators of inflammation (cytokines, 
chemokins, growth factors), correlation between 
the types of Th1- and Th2-lymphocyte immune 
response [1, 2, 4].  
Certain investigations showed that genetic fac-
tors of BA and obesity overlap each other [7–9]; 
this indicates that they have common genetic pre-
disposition. Thus, BA and obesity are associated 
with the genes, which encode ȕ-adrenergic recep-
tor (locus 5q, ADRB2 gene), insulin-like growth 
factor (locus 12q, IGF1 gene), IL-1Į (locus 12q, IL-
1Į gene), leukotriene A4 hydroxylase (locus 12q, 
LTA4H gene), GR (locus 5q, NR3C1 gene), signal 
transducers and activators of transcription (locus 
12q), TNF (locus 6p, TNF gene), uncou-pling 
protein (locus 11q13, gene UCP2 and 3), etc. [6]. 
 
Among candidate genes of obesity and BA 
there is a single copy of glucocorticoid receptor 
(GR) gene in humans and it is located on chro- 
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mosome 5 (locus 5q31.3). A few polymorphisms of 
this gene are described; they are related to anthro-
pometric parameters [10, 11]. The most common 
and well-studied polymorphism is BclI (C647G, 
rs41423247). Depending on population, G-allele 
frequency of the polymorphism constitutes more 
than 30 %. Some investigations have proved the 
association of BclI polymorphism with body mass 
index (BMI) and abdominal obesity [10, 11]; a few 
studies have shown its association with BA [12]. 
Still, no investigations related to the connection of 
BclI polymorphism with body mass index in BA 
patients were carried out.  
The objective of this investigation was to analyze 
possible association between BclI polymorphism of 
GR gene and obesity in patients with BA.  
Materials and methods. Prior to the study, all 
patients provided written informed consent to 
participate. 188 patients with BA have been 
examined. The control group consisted of 95 ap-
parently healthy adult individuals. Among 188 
patients with BA were 124 women (66 %) and 64 
men (34 %), in the control group – 50 (52.6 %) and 
45 (47.4 %) respectively. The average age of 
patients with BA accounted 46,2 ± 0,83 years, and 
for the control group – 44,1 ± 1,53 years. There 
were no statistically significant differences in the 
ethnic component in the control group and in the 
patients with BA. We measured body mass, height, 
body mass index (BMI), and deter-mined the ratio 
of fat centralization (RFC). BMI and RFC 
parameters were estimated according to WHO 
recommendations.  
The determination of allelic polymorphism in 
exon 2 of Bcl1 GR gene (C647G; rs41423247) was 
performed by means of polymerase chain reaction 
with subsequent analysis of restriction fragment 
length polymorphism (according to the instruc- 
 
tions of Fleury [15]) with modifications. Statistical 
analysis of the results was performed using SPSS-
17 program. The obtained results were subjected 
to descriptive statistical analysis with calculation of 
arithmetic means and standard deviations. The 
significance of differences between mean values 
was determined by means of Pearson Ȥ2, with P < 
0.05 adopted as the significance level. Logistic 
regres-sion, analysis of variance, Fisher criterion 
have been used as well.  
Results. The compliance test for Bcl1 polymor-
phism genotypes distribution and the Hardy-Wein-
berg equilibrium showed that deviations from the 
equilibrium were not statistically significant either in 
the control group (Ȥ2 = 0,01; p > 0,05), or in the 
main one (Ȥ2 = 3,53; p > 0,05), so the allele cor-
relations in both groups didn’t significantly differ 
from the predicted (ð > 0.05). The control group 
had the following genotypes frequency for Bcl1 
polymorphism of GR gene: C/C, Ñ/G, G/G – 
0,421/0,453/0,126, respectively. In patients with 
BA the frequency of studied genotypes made: 
0,228/0,426/0,346, respectively. Thus, the analysis 
of genotype frequencies for Bcl1 polymorphism of 
GR gene asserted that there is a statistically 
signifi-cant difference in the distribution of allelic 
variants of the gene between patients with BA and 
healthy individuals (Ȥ2 = 19,234; p = 0,001).  
Among patients with BA, normal body mass 
(NBM) was found in 50,5 % of individuals, over-
weight – 15,4 %, obesity – 34 %. In the control 
group, 76,8 % of the investigated had NBM, 20 % 
had overweight and 3,2 % had obesity. It was 
demonstrated that obesity occurs more often 
among BA patients, than in the control group (ð = 
0,001).  
The patients with BA had higher BMI para-
meter, than the individuals in the control group 
 
Table 1. Body mass index in the groups depending on the variations of genotype for Âcl1 
polymorphism of glucocorticoid receptor gene 
 
Groups  C/C  C/G  G/G F 
p
1 
Control 23.5 ± 0.46 (40) 23.6 ± 0.45 (43) 23.1 ± 0.61 (12) 0.093 0.9126 
BA 24.6 ± 0.68 (43) 25.2 ± 0.57 (80) 31.3 ± 0.74 (65) 30.39 0.0001 
ð
2  0.1905  0.0608  0.0001   
 
Note. F – Fisher criterion; ð1 – significance of the differences among genotypes according to the data of the one-way 
analysis of variance; ð2 – significance of the differences between the control group and BA patients according to the 
t-test; figures in the braces – the number of patients. 
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(27,2 ± 0,44 kg/m2 vs. 23,5 ± 0,29 kg/m2; ð < < 
0.001). Table 1 depicts indicators of BMI in control 
group and in patients with BA, which have dif-
ferent genotype by BclI polymorphism of the GR 
gene. The obtained data showed that BMI values 
didn’t significantly differ in carriers with different 
genotypes for BclI polymorphism in the control 
group (ð = 0,91). However, dependence between 
BclI polymorphism and BMI parameters was found 
in patients with BA: G/G genotype carriers had 
higher BMI (31,3 ± 0,74 kg/m2), than repre-
sentatives with others genotypes. Comparing the 
groups, we found out that BMI values didn’t differ 
significantly in C/C and C/G genotypes carriers. 
However, G/G homozygotes among BA patients 
had higher BMI, than those in the control group: 
31,3 ± 0,74 kg/m2 vs 23,1 ± 0,61 kg/m2 (ð = = 
0,0001).  
Table 2 represents the results obtained during 
the study of GR allelic variations distribution for 
BclI polymorphism in patients with BA and 
apparently healthy individuals having different BMI 
values. Differences in the distribution of different 
geno-type variations for BclI polymorphism of GR 
gene between patients with BA and apparently 
healthy individuals with normal body mass were 
not statisti-cally significant, because the ð value 
determined by Pearson’s chi-squared test (Ȥ2) was 
higher than 0,05 and equaled to 0,275, at same 
time this differences among BA patients and 
healthy individuals with increased body weight 
were statistically significant (ð = 0,0001).  
The analysis of genotypes distribution for this 
polymorphism in patients with BA showed signifi-
cant differences among patients with different body 
mass. P was lower, than 0,0001 by Pearson’s chi- 
 
squared test (Ȥ2). It was established that BA 
patients with obesity mostly had G/G genotype.  
The research on the visceral obesity frequency 
demonstrated that 78,9 % of apparently healthy 
individuals had normal ratio of fat centralization, 
while the rest had a higher ratio. Among the 
patients with BA, 54,8 % had a high ratio of fat 
centraliza-tion, 45,2 % had normal value. It was 
established that the patients with BA demonstrated 
higher ratio of fat centralization much more often, 
than others (ð = 0,0001).  
As comparing the data of genotype frequency for 
BclI GR gene polymorphism in the control group and 
BA patients group with normal fat centraliza-tion 
parameters, it was observed that the differences in 
distribution of GR gene allelic variations were not 
statistically significant (ð = 0,106). Where there was a 
higher ratio of fat centralization, a statistically 
significant difference in genotype distribution was 
reported (ð = 0,001) (Table 3).  
As comparing the data of genotype frequency for 
this polymorphism in exon 2 of GR gene in the control 
group and BA patients group with different fat 
centralization parameters, we found a statis-tically 
significant difference in the distribution of allelic 
variations only among the patients with BA. Thus, the 
analysis of genotypes distribution depend-ing on the 
ratio of fat centralization in patients with asthma 
showed a statistically significant difference (Ȥ2 = 25,5; 
ð = 0,001). C/G genotype was mostly found in 
patients without visceral obesity (56,3 %), while G/G 
genotype was peculiar for the patients with high ratio 
of fat centralization (52,9 %). Con-sequently, GG 
homozygotes have higher ratio of fat centralization, 
than the major allele homozygotes or heterozygotes. 
 
Table 2. Distribution of genotypes for Âcl1 polymorphism of glucocorticoid receptor gene 
depending on body mass index 
 
   BMI < 25 kg/m2     BMI • 25 kg/m2   
Genotype 
            
 Control  BA  Control  BA 
             
 n  % N  % n  % N  % 
             
C/C 29 39.7 27 28.4 11 50 16 17.2 
C/G 34 46.6 55 57.9 9 40,9 25 26.9 
G/G 10 13.7 13 13.7 2 9,1 52 55.9 
   Ȥ2 = 2.58; ð = 0.275     Ȥ2 = 17.641; ð = 0.001 
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We have studied BA risk depending on the geno-
type of Âcl1 GR gene polymorphism in patients. 
Taking Ñ/Ñ genotype as a reference one, we de-
monstrated that G/G homozygous type of GR ge-ne is 
likely to cause a fivefold increase of BA risk (OR = 
5.038, CI – 95 % 2.377–10.682, ð < 0.001).  
Odds ratio calculated for the association bet-
ween Bcl1 gene polymorphism and predisposition 
to visceral obesity in BA patients, thus G/G geno-
type carriers showed a higher risk of visceral obe-
sity comparing to the patients with C/C genotype 
(OR = 3.13, CI – 95 % 1.4–6.97; ð < 0.01). 
Discussion. The objective of our research was 
to study the role of the most common and well 
studied polymorphisms – BclI polymorphism in 
intron 2 of GR gene – in occurrence of obesity in 
BA pa-tients. It was reported in the literature that 
the BclI polymorphism of GR gene was associated 
with the accumulation of visceral fat, which is a risk 
factor for atherosclerosis, cardiovascular diseases, 
obesity and BA [10, 12].  
A number of studies demonstrated an association 
between G/G genotype for the BclI polymorphism and 
obesity. Thus, Rosmond et al. [7] figured out that G 
allele was related to increase of BMI, ratio of fat 
centralization, saggital diameter. Other inves-tigations 
also reported on the connection between G allele and 
visceral fat mass increase [8, 11]. Three large studies 
showed the connection between BclI polymorphism 
and visceral obesity among middle age individuals [7, 
8, 11]; moreover, G allele was associated with higher 
mass of visceral fat indepen-dent of the total body fat 
mass [8].  
BclI polymorphism was associated with ab-
dominal obesity, though a few studies found no 
significant differences in BclI polymorphism ge- 
 
notype frequency in individuals with or without 
obesity [13]. Our investigation established that BMI 
values didn’t differ much among the con-trol group 
individuals with different genotypes for Bcl1 GR 
gene polymorphism. However, the ana-lysis of 
genotypes distribution for this polymor-phism in 
patients with asthma showed significant 
differences among patients with different body 
mass (ð < 0,0001 by Ȥ2 Pearson’s chi-squared 
test. Thus, G/G genotype for BclI polymorphism 
was related to higher BMI as compared with other 
genotypes and the control group (ð = 0,0001). This 
indicated that body mass in patients with asthma 
depended on the genotype for Bcl1 GR gene 
polymorphism; besides, G/G genotype was related 
to the maximum BMI values.  
The connection between BMI and the 
genotypes for BclI polymorphism of GR gene in 
patients with BA, as well as the absence of such 
connection in the control group, is explained by the 
fact that G/G genotype frequency in the patients 
was higher, than that in apparently healthy 
individuals. These observations are congruent with 
the data given by Polish scientists [12]. In its turn, 
this can testify that G allele homozygotes are more 
predisposed to developing BA and obesity, than 
C/C homozygotes and heterozygotes. Therefore, 
BclI polymorphism is associated with occurrence of 
BA and obesity in patients with BA.  
The analysis of possible association between 
the genotypes for BclI GR gene polymorphism and 
visceral fat deposition stated no statistically sig-
nificant differences in the distribution of GR gene 
allelic variations, if the ratio of fat centralization is 
normal (ð = 0,106). In case of an increased ra-tio, 
differences in genotype distribution are present 
 
Table 3. Distribution of genotypes for Âcl1 polymorphism of glucocorticoid receptor gene 
depending on the ratio of fat centralization 
 
  Normal RFC   Increased RFC   
          
Genotype Control, n = 75 BA, n = 103 Control, n = 20  BA, n = 85 
          
 n % N % n % N  % 
          
C/C 29 38.7 25 24.3 11 55 18 21.2 
C/G 36 48.0 58 56.3 7 35 22 25.9 
G/G 10 13.3 20 19.4 2 10 45 52.9 
  Ȥ2 = 4.5; ð = 0.106   Ȥ2 = 13.9; ð = 0.001 
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(ð = 0,001). Thus, C/G genotype was mostly found in 
the patients without visceral obesity, while G/G 
genotype was peculiar for the patients having vis-
ceral obesity. On the other hand, it was observed that 
in the group of BA patients: 58,1 % of C/C genotype 
carriers had normal ratio of fat centraliza-tion and 
41,9 % had a high ratio; C/G genotype carriers had 
72,5 and 27,5 %, respectively; G/G genotype carriers 
had 30,8 and 69,2 %, respectively. It was found out in 
the patients with BA that G/G homozygotes have 
higher ratio of fat centralization, than the major allele 
homozygotes or heterozygotes. The analysis of 
genotypes distribution depending on the ratio of fat 
centralization in patients with asthma showed a 
statistically significant difference (Ȥ2 = 25,5; ð = 
0,001).  
Therefore, the obtained data concerning the 
association of G/G genotype for BclI GR gene 
polymorphism with the occurrence of BA, obesity 
(particularly, visceral type) verify possible common 
genetic origin of these two diseases and pleiotropic 
features of BclI polymorphism.  
Molecular mechanisms of how BclI polymor-
phism influences the occurrence of obesity are not 
clearly determined yet; they can be related to the 
direct influence of the Bcl1 polymorphism on GR 
gene expression, as well as to its possible 
influence on the transcriptional activity of target 
genes, involved in glucose and insulin homeostasis 
[10]. This polymorphism is probably connected with 
other polymorphisms in the promoter region of GR 
gene, as well as with other polymorphisms in other 
genes.  
The mechanisms due to which the BclI poly-
morphism can influence BA occurrence remain un-
clear. This influence can be possibly explained by 
the results of the studies demonstrating the effect 
of this polymorphism on sensitivity to glucocortico-
steroids and obesity occurrence, which can induce 
BA and complicate BA course [10, 12].  
The obtained results as for the association be-
tween BclI GR gene polymorphism and occurrence 
of BA and obesity require further research on the 
complicated molecular mechanisms – this will en-
able better understanding of occurrence principles 
of obesity-associated BA, and will help to develop 
new individual therapy approaches, respectively.  
Conclusions. It was found out that the patients 
with BA demonstrated higher BMI and ratio of fat 
centralization much more often, than the control 
 
group (ð = 0,0001). Genotypes distribution for BclI 
polymorphism in patients with BA showed a 
statistically significant difference between pa-tients 
with different BMI unlike the control group. G 
homozygotes had higher BMI, than those in the 
control group or with other genotypes. BMI didn’t 
much differ between C/C and C/G geno-types 
carriers. Comparison of genotype frequency for 
BclI GR gene polymorphism in individuals with 
different ratio of fat centralization in the control 
group and in the patients with BA sepa-rately 
showed statistically significant differences in the 
distribution of gene allelic variations among the 
patients with BA only. Among BA patients with G/G 
genotype – 69.2 % had visceral obe-sity. In case of 
normal ratio of fat centralization, there were no 
statistically significant differences in the distribution 
of allelic variations between the control group and 
in the patients with BA. It was found out that G/G-
homozygotes have a fivefold higher risk of BA, than 
those homozygous for C/C. We demonstrated that 
risk of visceral obesity in BA patients, homozygous 
for the minor allele, is 3.13 times higher, as 
compared with Ñ/Ñ-homozygotes (ð < 0.001). 
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